Trazodone Dosage: Sleep Dose vs Depression Dose Explained

Trazodone is a single molecule that treats two very different problems at two very different doses, and mixing up which dose belongs to which problem is one of the more common sources of confusion in psychiatric prescribing. A dose that helps someone sleep can be a fraction of the dose that treats their depression, and understanding why requires looking at what trazodone actually does to serotonin, histamine, and adrenaline receptors as the dose climbs.

What This Page Covers

• Two Doses, Two Mechanisms
• The FDA-Approved Dose for Depression
• The Off-Label Dose Range for Sleep
• What the Sleep Guidelines Actually Say
• Safety Warnings That Apply at Any Dose
• About Siggy

Two Doses, Two Mechanisms

Trazodone belongs to a drug class called serotonin antagonist and reuptake inhibitors, and its effects genuinely change character as the dose increases. At low doses, roughly 25 to 100 mg, the dominant effect comes from blocking the serotonin 5-HT2A receptor along with histamine H1 and alpha-1 adrenergic receptors, a combination that produces sedation without much impact on mood. According to a National Institutes of Health StatPearls review of trazodone’s pharmacology, this receptor profile is what produces the drug’s hypnotic effect at low doses, distinct from its antidepressant mechanism.

Antidepressant efficacy requires meaningfully blocking serotonin reuptake at the same time as the 5-HT2A receptor, and that combination becomes more significant at higher doses, generally around 150 mg and above. Increasing a dose within the lower sleep range may increase sedation, but it can also increase next-day drowsiness, dizziness, and orthostatic hypotension; it is not a risk-free way to improve sleep. Because the medication’s effects and risks change with dose, any increase should be set by a prescriber rather than tried independently.

The FDA-Approved Dose for Depression

Trazodone’s only FDA-approved indication is major depressive disorder, and its labeled dosing reflects the higher-dose mechanism described above. The FDA prescribing information for DESYREL sets the initial dose at 150 mg per day in divided doses, which may be increased by 50 mg per day every 3 to 4 days as tolerated, up to a maximum of 400 mg per day in outpatients or 600 mg per day in a hospitalized setting.

Dividing the daily dose across the day, rather than taking it all at once, is part of the labeled approach for depression, since higher single doses raise the risk of daytime sedation and orthostatic hypotension. As with other antidepressants, the full effect on mood is not immediate. Most patients need 2 or more weeks at an adequate dose before a meaningful antidepressant response becomes clear, which is the same general timeline used to judge whether other antidepressants are working.

The Off-Label Dose Range for Sleep

Insomnia is not an FDA-approved use for trazodone, but it accounts for the majority of its real-world prescriptions. Off-label sleep dosing looks nothing like the depression schedule above. Most prescribers start at 25 to 50 mg at bedtime, and many patients settle into an effective range between 25 and 100 mg, well under the 150 mg floor used for depression.

Use	Typical Starting Dose	Typical Range	FDA-Approved
Major depressive disorder	150 mg/day, divided	Up to 400 mg/day (600 mg in hospital)	Yes
Insomnia (off-label)	25 to 50 mg at bedtime	25 to 100 mg, rarely to 150 mg	No

A systematic review of 45 studies on trazodone for insomnia found evidence supporting the efficacy and general safety of low-dose trazodone for sleep, while noting that side effects are dose-dependent and that the drug’s role expanded from treating insomnia in depressed patients toward broader use in non-depressed patients since the 2000s. That same review reported the most common side effect at low doses is drowsiness, which is the intended effect when the drug is used for sleep rather than an unwanted one.

What the Sleep Guidelines Actually Say

Widespread off-label use is not the same as a guideline recommendation, and it is worth being direct about the gap between the two for trazodone. The American Academy of Sleep Medicine’s 2017 clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults explicitly suggests that clinicians not use trazodone as a treatment for sleep-onset or sleep-maintenance insomnia, a weak recommendation reflecting the limited quality of trial evidence rather than a finding that the drug does not work. The same guideline recommends cognitive behavioral therapy for insomnia as the preferred first-line approach before medication of any kind.

This does not mean trazodone is unsafe or ineffective for sleep in an individual patient. It means the guideline-level evidence is weaker than the prescribing pattern might suggest, which is useful context when deciding whether to try it, switch away from it, or combine it with non-drug approaches like consistent sleep timing and stimulus control.

Safety Warnings That Apply at Any Dose

A few of trazodone’s warnings do not scale down with a lower sleep dose the way people sometimes assume. The FDA label documents that trazodone may be arrhythmogenic in patients with preexisting cardiac disease, and postmarketing reports of QT prolongation and torsade de pointes have occurred at doses of 100 mg per day or less, meaning the low sleep dose is not automatically a low cardiac risk dose for someone with an existing arrhythmia history.

Trazodone also carries a rare but serious risk of priapism, a prolonged and potentially damaging erection, which the label lists as a reason for immediate medical attention if an erection lasts longer than 4 hours. Like most antidepressants, it carries the FDA’s boxed warning for increased risk of suicidal thinking and behavior in children, adolescents, and young adults, particularly early in treatment or after a dose change. Combining trazodone with alcohol or other sedating medications increases the risk of excessive sedation regardless of which dose range it falls into.

About Siggy

Trazodone’s split identity, one drug with two different jobs at two different doses, is a good example of why dose changes need a prescriber’s eyes on them rather than a patient’s own trial and error. A dose that feels too weak for sleep is not automatically safe to double, and a dose adjusted for depression symptoms is not automatically fine to shift for sleep purposes without a conversation first.

If trazodone or another antidepressant is part of your care and you want someone tracking how a dose change is actually affecting your sleep, mood, and side effects between appointments, that ongoing check-in is what Siggy is built to provide alongside a licensed prescriber. Start your anonymous intake with Siggy to get that support in place.